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long-term arrhythmic beating in hiPSC-CMs accompanied 
by significant cytotoxicity. Global gene expression changes 
were studied using microarrays and bioinformatics tools. 
Analysis of the transcriptomic data revealed early expres-
sion signatures of genes involved in formation of sarcom-
eric structures, regulation of ion homeostasis and induction 
of apoptosis. Eighty-four significantly deregulated genes 
related to cardiac functions, stress and apoptosis were vali-
dated using real-time PCR. The expression of the 84 genes 
was further studied by real-time PCR in hiPSC-CMs incu-
bated with daunorubicin and mitoxantrone, further anthra-
cycline family members that are also known to induce 
cardiotoxicity. A panel of 35 genes was deregulated by all 
three anthracycline family members and can therefore be 
expected to predict the cardiotoxicity of compounds act-
ing by similar mechanisms as doxorubicin, daunorubicin 
or mitoxantrone. The identified gene panel can be applied 
in the safety assessment of novel drug candidates as well 
as available therapeutics to identify compounds that may 
cause cardiotoxicity.
Keywords Cardiotoxicity · Human stem cells derived 
cardiomyocytes · Heart failure · Transcriptomics · Genomic 
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Introduction
Drug-induced cardiotoxicity is a major safety issue and 
has to be considered during drug development. Various 
in vivo and in vitro assays have been developed to assess 
the adverse effect of lead compounds on cardiac functions. 
Due to interspecies physiological differences, these assays 
often do not correctly predict the actual adverse effects of 
drug candidates on the human heart. Moreover, traditional 
Abstract The currently available techniques for the safety 
evaluation of candidate drugs are usually cost-intensive and 
time-consuming and are often insufficient to predict human 
relevant cardiotoxicity. The purpose of this study was to 
develop an in vitro repeated exposure toxicity methodology 
allowing the identification of predictive genomics biomark-
ers of functional relevance for drug-induced cardiotoxicity 
in human induced pluripotent stem cell-derived cardiomyo-
cytes (hiPSC-CMs). The hiPSC-CMs were incubated with 
156 nM doxorubicin, which is a well-characterized cardio-
toxicant, for 2 or 6 days followed by washout of the test 
compound and further incubation in compound-free cul-
ture medium until day 14 after the onset of exposure. An 
xCELLigence Real-Time Cell Analyser was used to moni-
tor doxorubicin-induced cytotoxicity while also monitor-
ing functional alterations of cardiomyocytes by counting 
of the beating frequency of cardiomyocytes. Unlike sin-
gle exposure, repeated doxorubicin exposure resulted in 
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approaches to toxicological testing involve extensive ani-
mal studies, thus making testing costly and time-consum-
ing. Although primate and human primary cardiomyocytes 
represent highly relevant cell systems, their use is limited 
by ethical reasons and difficult availability (Anson et al. 
2011). Above all, the pharmaceutical industry is strug-
gling with the costly withdrawal of drugs from the market 
due to toxic effects, often related to cardiotoxicity (Tafuri 
et al. 2013). Therefore, there is an urgent need for the 
development of a sensitive, robust and clinically relevant 
in vitro system with cardiomyocytes for efficacy and safety 
assessment.
Human embryonic stem cells (hESCs) and human 
induced pluripotent stem cell (hiPSC)-derived cardiomyo-
cytes have a high physiological relevance and show typi-
cal drug-induced changes in electrophysiological proper-
ties (Caspi et al. 2009; Reppel et al. 2005; He et al. 2003). 
Reproducible and large-scale production of highly purified 
hESCs/hiPSC-derived cardiomyocytes (hESC-CMs/hiPSC-
CMs) makes them an attractive source for human cardio-
toxicity tests. It is expected that human cardiomyocytes 
will increase the predictive ability of the adverse effects of 
potential drugs in humans and may replace or reduce car-
diac safety assessment assays based on animal-derived pri-
mary cardiomyocytes or cardiac ion channel overexpress-
ing cell lines (Steel et al. 2009).
Among anti-cancer drugs, anthracycline family mem-
bers such as doxorubicin, daunorubicin and mitoxantrone 
are known to induce cardiotoxicity (Menna et al. 2012; 
Paul et al. 2007). Multiple mechanisms such as free radi-
cal formation, lipid peroxidation and DNA damage have 
been proposed to explain the cardiotoxicity of anthracy-
clines. Additionally, interactions of anthracyclines with 
the DNA-topoisomerase complex or directly with DNA 
by intercalation result in disturbances in DNA replica-
tion and transcription and have been extensively studied 
(Minotti et al. 2004). Dose-dependent cardiotoxicity of 
anthracyclines limits their therapeutic application. Drugs 
that do not compromise the electrophysiology of the heart 
can also be cardiotoxic by directly damaging cardiomyo-
cytes at both the subcellular and molecular levels via the 
formation of reactive oxygen species, DNA damage, mito-
chondrial damage, apoptosis or disturbed molecular sig-
nalling events. Elevated levels of cardiac troponin I (cTnI) 
and cardiac troponin T (cTnT) in blood correlate well with 
myocardial injury and act as critical plasma biomarkers for 
the diagnosis of cardiac damage in clinical and preclinical 
studies (Babuin and Jaffe 2005; O’Brien 2008; Tonomura 
et al. 2009). However, high levels of these biomarkers 
occur only after cardiac damage and can be detected for 
only a few hours after myocardial infarction and cardio-
toxic drug treatment. To avoid drug-induced cardiotoxicity 
in the future, there is an urgent need to develop sensitive 
and reliable methods to detect or predict early cardiotoxic 
events.
In the present study, well-characterized hiPSC-CMs 
were used as an in vitro system of cardiotoxicity in com-
bination with transcriptomics. Among the anthracyclines, 
doxorubicin is one of the most successful agents for solid 
and haematological malignancies in both children and 
adults. Doxorubicin has been extensively studied in a vari-
ety of preclinical models and clinical phases. Here, we 
developed a methodology allowing single and repeated 
chronic exposures of human cardiomyocytes to doxoru-
bicin (156 nM). The cardiotoxic effects of doxorubicin 
were monitored by real-time counting of the beating activ-
ity and cytotoxicity. Moreover, global gene expression 
changes were studied using a transcriptomic approach. 
Doxorubicin-deregulated expression signature of genes was 
further analysed in a follow-up study using daunorubicin 
and mitoxantrone, which also belong to the anthracycline 
family. Our study demonstrates that the integrative use of 
the xCELLigence Real-Time Cell Analyser (RTCA) cardio 




All experiments were performed with purified human iCell 
Cardiomyocytes® (Cellular Dynamics International, Madi-
son, WI, USA), which were derived from hiPSCs. The car-
diomyocytes were supplied as a cryopreserved single cell 
suspension of a 98 % pure population. The cardiomyocytes 
were a mixture of spontaneously electrically active atrial-, 
nodal- and ventricular-like myocytes. These cells exhibit 
typical biochemical, electrophysiological and mechanical 
characteristics of normal human heart cells with expected 
responses upon exposure to exogenous agents. Cryopre-
served hiPSC-CMs were thawed in iCell cardiomyocytes 
plating medium (iCell-PM, Cellular Dynamics Interna-
tional, Madison, WI, USA) per the manufacturer’s instruc-
tions. For functional studies, thawed cells were directly 
plated on a fibronectin-coated (5 µg/cm2, 2 h at 37 °C) 
E-plate Cardio 96 (ACEA Biosciences, San Diego, CA, 
USA) at approximately a 25 × 103 cells per well density 
using iCell-PM. For transcriptomic studies, thawed cells 
were plated on fibronectin-coated (5 µg/cm2, 2 h at 37 °C) 
6-well plates at a 0.4 × 106 per well cell density. Two days 
later, cells were maintained in iCell cardiomyocyte Main-
tenance Medium (iCell-MM, Cellular Dynamics Interna-
tional, Madison, WI, USA), with a fresh medium change 
after every 2 days. The cardiomyocytes were cultured in a 




The 10 mM stock solutions (in DMSO) of doxorubicin, 
daunorubicin and mitoxantrone were purchased from Sell-
eck Chemicals. Stock solutions were stored as small vol-
ume aliquots in tightly sealed sterile tubes at −80 °C. Drug 
dilutions were performed in pre-warmed (37 °C) iCell-MM 
prior to each drug exposure. Doxorubicin was used as the 
gold standard reference compound to develop experimental 
methodology.
xCELLigence RTCA Cardio system
The xCELLigence RTCA Cardio system (ACEA Bio-
sciences, San Diego, CA, USA) is an impedance-based 
platform for monitoring the real-time beating function of 
cardiomyocytes. It was used to sensitively and quantita-
tively detect pro-arrhythmic drug effects on cardiac func-
tion and to measure cell viability in real time. Impedance 
measurements were monitored at regular time intervals. 
The amount of growth area covered in an E-plate Cardio 
96 due to cell adhesion was represented as the Cell Index 
(CI). A high CI indicates more cell adhesion. Before cell 
plating, the background impedance of E-plate Cardio 96 
(ACEA Biosciences, San Diego, CA, USA) was meas-
ured using iCell-PM (50 µl per well). The raw data of cell 
viability, beating activity and the beating amplitude were 
acquired using the xCELLigence RTCA Cardio system and 
analysed using RTCA Cardio software version 1.0 (ACEA 
Biosciences, Inc, San Diego, CA, USA).
RNA extraction
Cell samples were homogenised with QIAzol lysis rea-
gent (Qiagen, Hilden, Germany), and the total RNA was 
extracted and purified using the RNeasy mini kit (Qia-
gen, Hilden, Germany) according to the manufacturer’s 
instructions. A Nanodrop (ND-1000, Thermo Fisher, Lan-
genselbold, Germany) was used for RNA quantification 
and purity assessment. RNA integrity was confirmed using 
the Experion™ automated electrophoresis system (Bio-
Rad, Munich, Germany). Extracted RNA was subjected to 
human gene array processing using Affymetrix’s kits, rea-
gents and instrument setup.
Microarray labelling and hybridization
For microarray gene expression studies, 100 ng of total 
RNA was used as a starting material. The total RNA sam-
ples were amplified and labelled using GeneChip 3′ IVT 
Express Kit per the manufacturer’s instructions (Affym-
etrix, High Wycombe, UK). The amplified biotin-labelled 
RNA (aRNA) samples were purified using magnetic beads, 
and 15 µg of aRNA was fragmented with fragmentation 
buffer per the manufacturer’s instructions. Then, 12.5 µg 
of fragmented aRNA was used to hybridize with Affym-
etrix Human Genome U133 plus 2.0 array along with the 
hybridization cocktail solution. For microarray hybridiza-
tion, gene chips were placed in a GeneChip Hybridization 
Oven-645 (Affymetrix, High Wycombe, UK) for 16 h at 
60 rpm and 45 °C. After incubation, the arrays were washed 
and stained using the Affymetrix HSW kit on GeneChip 
Fluidics Station-450. The stained arrays were scanned with 
Affymetrix GeneChip Scanner-3000-7G, and image and 
quality control assessments were performed with Affym-
etrix GCOS software. The generated CEL files were used 
for further statistical analysis.
Microarray statistical data analysis and functional 
annotation analysis
Array raw data were quantile normalized using the RMA 
implementation of the R Affy package (Gautier et al. 
2004). Differential expression was determined by the linear 
model implementation of the R Limma package (Minotti 
et al. 2004) followed by a Benjamini Hochberg multiple 
testing correction (1 % FDR). To specifically determine the 
perturbed transcripts, the expression level of transcripts in 
the doxorubicin (156 nM)-exposed cell samples was pair-
wise compared with that of day 2 and day 6 control cell 
samples, while doxorubicin washout cell sample transcripts 
were compared with day 14 control cell sample transcripts. 
The size of change was stated with a threshold value of 
fold change 2 in absolute scale. Choosing only significantly 
expressed probe sets, k-means cluster analysis was per-
formed after transcript-wise normalization of signal values 
to a mean of 0 and an SD of 1 using Euclidean distance 
measurement and k = 6, using the Cluster 3.0 tool from the 
Eisen laboratory (Eisen et al. 1999). To further investigate 
biological functions and the pathway involvement of genes, 
Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) was used for functional annotation and 
gene ontology (GO) clustering (Dennis et al. 2003). The 
GeneCards database was also used to investigate annotative 
information about genes and its relation to human cardiac 
disorders (Safran et al. 2010).
mRNA expression analysis using RT2 profiler PCR 
arrays and real‑time PCR
Using 300–500 ng of total RNA, a genomic DNA elimina-
tion step and cDNA synthesis were performed with the RT2 
First Strand kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. For quantitative comparison 
of mRNA levels, real-time PCR was performed using cus-
tom made RT2 Profiler PCR array (96-well plate) (Qiagen, 
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Hilden, Germany). This array contained 84 target genes, 
5 housekeeping genes, 1 genomic DNA control, 3 reverse 
transcription controls and 3 positive PCR controls. Real-
time PCR was performed using RT2 SYBR® Green ROX™ 
qPCR master mix in an Applied Biosystems 7500 FAST 
Real-Time PCR System in accordance with the manufactur-
er’s recommended thermal cycling conditions. The relative 
gene expression analysis was performed using the 2−ΔΔCt 
method with the RT2 PCR array data analysis online tool. 
Expression data were normalized using the geometric mean 
of 5 housekeeping genes—ACTB, B2M, GAPDH, HPRT1 
and RPLP0. A cut-off fold change value of 1.9 was set for 
significantly deregulated genes and later used to generate 
the gene list used for Venn diagram analysis.
Immunostaining
For immunocytochemistry analysis, control, doxorubicin-
exposed and washout iPSC-CMs were fixed with ice-cold 
99 % methanol (Roth, Karlsruhe, Germany) for 10 min at 
−20 °C. Then, cells were permeabilized with 0.3 % Triton 
X-100 (Sigma-Aldrich, Steinheim, Germany) for 20 min 
at room temperature. Cells were blocked with 5 % bovine 
serum albumin (Sigma, Steinheim, Germany) for 1 h at 
room temperature and incubated with anti-sarcomeric 
alpha actinin (Abcam, 1:200) and anti-cardiac troponin T 
(Abcam, 1:200) for 1 h at 37 °C. The cells were washed 3 
times with phosphate-buffered saline (PBS) with Ca2+ and 
Mg2+ for 5 min. Primary antibodies were detected using 
species matched respective Alexa Fluor-488/568-conju-
gated secondary antibodies (Invitrogen, Darmstadt, Ger-
many) with 1 h incubation at 37 °C. The cells were washed 
3 times with PBS for 5 min and then mounted with Pro-
long® Gold anti-fade mount with DAPI (Invitrogen, Darm-
stadt, Germany). Cell images were taken with an Axiovert 
200 fluorescence microscope and Axiovision 4.3 software 
(Carl Zeiss).
Results
Experimental setup for single and repeated exposure
Cryopreserved hiPSC-CMs were thawed, and after 4 days 
of cultivation, synchronously beating cardiomyocytes 
were exposed to doxorubicin according to the timeline 
schematically represented in Fig. 1. In brief, an experi-
mental setup with single 2-day exposure periods to doxo-
rubicin (156 nM, DOX-Day2) or three consecutive expo-
sure periods to doxorubicin (DOX-Day6) (doxorubicin 
supplemental media refreshed every 48 h) was applied. 
Until day 6, control cells were cultured in iCell-MM with-
out doxorubicin but with DMSO as a solvent. Thereafter, 
cardiomyocytes were further cultivated in doxorubicin-free 
iCell-MM till day 14 after the start of drug exposure. Cul-
ture medium changes were performed every 2 days. For the 
functional studies, beating and viability data from doxoru-
bicin-exposed cardiomyocytes were obtained by the xCEL-
Ligence RTCA Cardio system. For transcriptomic stud-
ies, doxorubicin-exposed cardiomyocytes were harvested 
on day 2 and day 6, respectively, whereas day 2 washout 
(DOX-Day2WO) and day 6 washout (DOX-Day6WO) cells 
were harvested on day 14. RNA isolated from the harvested 
cells was further analysed by gene array. The time frame 
Fig. 1  Schematic representation and experimental setup of the 
in vitro cardiotoxicity test system. Four days post-cell plating, the 
synchronously beating hiPSC-CMs were exposed to drug/test com-
pound either for a single 2-day exposure period (single exposure) 
or for 6 days, consisting of 3 culture medium changes every 2 days 
(repeated exposure). After exposure, the drug/test compound was 
washed out and the cells were further incubated until day 14. For 
functional studies, hiPSC-CMs were seeded in the E-plate Cardio 
96 and the influence of drug/test compound on cardiomyocytes was 
monitored by the xCELLigence RTCA Cardio system. For transcrip-
tomics studies, RNA of drug/test compound exposed cells was har-
vested at day 2 and day 6, and after washout at day 2 and day 6, RNA 
samples were collected at day 14. Control cellular RNA samples were 
also harvested at the corresponding time points at day 2, 6 and 14
Fig. 2  Functional studies of doxorubicin-exposed hiPSC-CMs using 
the xCELLigence RTCA Cardio system. a The representative graph 
displays doxorubicin repeated exposure induced cytotoxicity show-
ing a decrease in normalized Cell Index values. In the graph, DOX-
SE indicates doxorubicin single exposure and DOX-RE represents 
doxorubicin repeated exposure. Cell Index normalization was per-
formed at a Cell Index value of 7.0. The numerical data represent 
means ± standard deviations (SD) (n = 3). b Influence of single and 
repeated doxorubicin exposures (156 nM) on cell density and mor-
phology. The scale bar represents 50 µm. c Doxorubicin single and 
repeated exposures induced changes in % beating rates. Basal beat-
ing rate of cardiomyocytes was from 25 to 32 per min at threshold 
10. Data show the mean ± SD (n = 3). ***Indicates p value <0.005. 
d Representative 12 s beating traces of hiPSC-CMs after doxoru-
bicin single and repeated exposures and during drug washout. In 
each graph Y-axis represents normalized Cell Index (Nor. CI). Beat-
ing activity illustrates the development of arrhythmic beating upon 
repeated exposure and also in surviving cells after repeated exposure. 
e In contrast to single exposure, repeatedly exposed cells showed a 
significant decrease in beating amplitude when compared to control 
cells. Bar graph numerical values represent mean ± SD (n = 3). 




from day 4 and day 18 was chosen for the present study 
because hiPSC-CMs (after cell plating) can be cultured in 
an E-plate cardio 96 until day 18–19 without losing cell 
viability. Moreover, the cells showed synchronous beat-
ing behaviour from day 4 onwards. In addition, the initial 
concentration-dependent cytotoxicity studies demonstrated 
that doxorubicin at 156 nM was still in a range that causes 
<10 % cell death, and its influence on beating rate was also 
less than 30 %. In contrast, doxorubicin concentrations 
higher than 156 nM increased cytotoxicity and arrhythmic 
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beating in hiPSC-CMs in a concentration-dependent man-
ner (Supplementary Figs. S1 and S2).
Repeated exposure to doxorubicin induced arrhythmic 
beats in cardiomyocytes
Repeated doxorubicin exposure induced a decrease in nor-
malized Cell Index values, which indicates a decrease in 
cell viability (Fig. 2a). During drug washout, especially 
in repeatedly exposed cells, a decrease in Cell Index val-
ues was observed but at a slow rate. Repeated doxoru-
bicin exposure induced cytotoxicity with a loss of cells in 
the doxorubicin DOX-Day6 and DOX-Day6WO groups 
(Fig. 2b). Analysis of data on beating cardiomyocytes 
showed that repeated doxorubicin exposure increased the 
beating rate at day 4 (DOX-Day4), and the same effect 
was still observed after long-term drug washout (Fig. 2c), 
whereas repeated exposure at day 6 decreased the beating 
rate (data not shown). This may be due to the cytotoxic 
effect of doxorubicin on cardiomyocytes under these expo-
sure conditions. Compared to controls, doxorubicin sin-
gle exposure did not influence beating rates significantly 
during exposure and washout. Representative changes in 
beating activity were captured after doxorubicin exposure 
and washout (Fig. 2d). Arrhythmic beating activity was 
observed in DOX-Day6 and DOX-Day6WO cells. Unlike 
DOX-Day2 cells, repeated exposure caused a significant 
decrease in the beating amplitude during exposure and 
washout (Fig. 2e). This may be explained by the decreased 
number of cells contributing to the total contraction.
Genome‑wide analysis of cells with and 
without doxorubicin washout identifies clusters 
of reversibly and irreversibly altered genes
To obtain an overview of genome-wide gene expression 
alterations induced by the different exposure schedules to 
doxorubicin, principal component analysis (PCA) was per-
formed based on the significantly altered transcripts (FDR 
p value <0.05; fold change ≥2.0) (Fig. 3a). The first com-
ponent PC1 described 64 % of the variance of the data and 
showed clear separation between controls and doxorubicin-
exposed and washout samples. The second component 
(PC2) described 10 % of the variance within the data and 
represented the distance between samples with and without 
washout. During the drug washout period, DOX-Day2WO 
returned almost to control levels, whereas DOX-Day6WO 
showed a much smaller degree of recovery. Genes with at 
least twofold changes in expression values were identified 
and analysed by k-means clustering (Fig. 3b). This tech-
nique identified clusters of genes with different response 
patterns to doxorubicin and also distinct reversibility after 
washout of the test compound. Cluster 1 genes showed 
up-regulation after doxorubicin exposure, but returned to 
basal levels after drug washout (Fig. 3b). The strongest 
overrepresented GO terms in this cluster represented genes 
involved in nucleosome organization and DNA-protein 
complex assembly (Table 1). Cluster 2 genes were up-reg-
ulated by doxorubicin exposure and interestingly remained 
up-regulated even after washout of the test compound 
(Fig. 3b). In this cluster, endoplasmic reticulum genes and 
the endoplasmic reticulum-nuclear signalling pathway were 
overrepresented. Genes in cluster 3 were down-regulated 
by doxorubicin and mostly recovered after the washout 
(Fig. 3b). Interestingly, the strongest overrepresented GO 
groups in this cluster were associated with the sarcomere, 
myofibrils, contractile fibre part and regulation of heart 
contraction. Therefore, cluster 3 contains genes that were 
clearly associated with normal heart function and therefore 
should be of high interest as biomarkers of cardiotoxicity. 
Expression of cluster 4 genes was up-regulated upon doxo-
rubicin exposure and decreased again after washout of the 
test compound, although not completely to control levels. 
Cluster 4 genes represented a cell stress response, with 
the p53 signalling pathway and apoptosis GO terms being 
overrepresented. Cluster 5 was a relatively small group of 
genes that were down-regulated after doxorubicin exposure 
and included overrepresented endogenous metabolism and 
extracellular matrix genes. Cluster 6 genes were down-reg-
ulated by doxorubicin and remained repressed even after 
washout. A strong overrepresentation of mitosis-associated 
genes occurred in this cluster. The genes of the individual 
clusters are listed in Supplemental Table 1, and all signifi-
cant GO groups of the clusters are provided in Supplemen-
tal Table 2. 
Doxorubicin exposure down‑regulates genes of cardiac 
function and up‑regulates stress‑associated genes
Doxorubicin exposure led to 2195 differentially expressed 
probe sets (FDR p value <0.05; fold change ≥2), which 
were used for further analysis. Venn diagram analysis of 
deregulated genes between DOX-Day2 and DOX-Day6 dis-
played a list of 462 mutually down- and 376 mutually up-
regulated genes (Fig. 3c, d). These commonly down- and 
up-regulated genes were used separately for GO enrich-
ment analysis using the DAVID functional enrichment tool. 
This analysis led to the identification of early doxorubicin-
responsive cardiac processes, pathways and general toxic 
responses. The GO analysis showed that down-regulated 
genes were mainly enriched in GOs such as muscle con-
traction, sarcomere, cytoskeleton and 6 KEGG pathways 
(Table 2), whereas up-regulated GOs were mainly enriched 
in cell death, anti-apoptosis, DNA damage stimulus, oxida-
tive stress responses and the KEGG pathways such as the 
p53 signalling pathway and apoptosis (Table 3). 
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Fig. 3  Doxorubicin-induced differential gene regulation in cardio-
myocytes. a 2D Principal component analysis (PCA) showed that 
doxorubicin exposure induces changes in gene expression depend-
ing on the exposure period. Each of the four replicates obtained 
from independent experiments is shown in single-coloured solid 
spheres. b k-means clustering analysis of 2195 transcripts differen-
tially expressed between day 2, 6 and 14. Differentially expressed 
transcripts were grouped into six clusters based on their expression 
pattern upon doxorubicin exposure and washout (a, b FDR p value 
<0.05; fold change ≥2.0). c, d Venn diagrams illustrating overlapping 
down- and up-regulated genes between DOX-Day2 and DOX-Day6 
groups. e, f Venn diagrams representing long-term down- and up-
regulated genes amongst all four experimental groups—DOX-Day2, 
DOX-Day6, DOX-Day2WO and DOX-Day6WO
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Moreover, Venn diagram analysis of deregulated genes 
in DOX-Day2, DOX-Day6, DOX-Day2WO and DOX-
Day6WO revealed 116 down- and 46 up-regulated genes, 
which did not recover during the washout period and 
showed long-term deregulation (Fig. 3e, f). These 46 up-
regulated genes had enriched GOs such as apoptosis, 
DNA damage, stress-responsive processes and the KEGG 
p53 signalling pathway (Table 4), whereas down-regu-
lated genes did not show significant enrichment in car-
diac- and toxicity-related biological processes as well as 
in the KEGG pathways. This analysis suggests that doxo-
rubicin negatively affected the expression of many car-
diac genes, which are essential for an intact function of 
cardiomyocytes.
Validation of deregulated genes by real‑time PCR 
and follow‑up by further cardiotoxic compounds
From the above-described transcriptomic data and GO 
results, 84 significantly early and/or long-term deregulated 
genes were selected to validate their mRNA levels using 
real-time PCR. Most of them belong to cluster 3 (Fig. 3b), 
which was considered as particularly relevant because 
it represents contractile fibres and myofibril-associated 
genes. This gene panel includes 50 down- and 34 up-reg-
ulated doxorubicin-induced genes with at least a twofold 
change. Selected genes were mostly cardiac specific with 
involvement in cardiac contraction (preferably sarcomeric 
genes), ion homeostasis, cardiac physiology and patho-
physiology, whereas another set of genes were associ-
ated with apoptosis, DNA damage and stress responses. 
Out of 84 genes, 63 genes were consistently deregulated 
upon doxorubicin single and repeated exposure (except 
LIF and CALM1, which were deregulated upon repeated 
exposure) and showed recovery during the washout 
period. Another 19 genes did not show full recovery dur-
ing washout. Along with doxorubicin transcriptomic data 
validation, differential regulation of these 84 genes was 
also investigated in hiPSC-CMs incubated with daunoru-
bicin (10 nM) and mitoxantrone (3 nM) using real-time 
PCR. The daunorubicin and mitoxantrone test concentra-
tions were determined using dose-dependent studies in 
hiPSC-CMs after 48 h of drug exposure (Supplementary 
Fig. S1). The selected test concentrations of daunorubicin 
and mitoxantrone did not induce cytotoxicity by more than 
10 % and also did not significantly influence beating rate 
or beating activity compared to controls (Supplementary 
Fig. S2–S4). Real-time PCR analysis revealed the deregu-
lation of 65 genes in the doxorubicin group and confirmed 
the transcriptomics results by 77.4 %. The daunorubicin 
and mitoxantrone groups showed the deregulation of 41 
genes in each group. Venn diagram analysis of the doxoru-
bicin, daunorubicin and mitoxantrone groups displayed 35 
commonly influenced genes: 27 down- and 8 up-regulated 
genes (Fig. 4a, b; Table 5). 
Doxorubicin‑induced sarcomeric deterioration
Our results showed that doxorubicin single exposures 
induced the down-regulation of sarcomeric genes. To inves-
tigate the effect of doxorubicin single and repeated expo-
sures on proteins relevant for sarcomere structure, cardiac 
troponin T and sarcomeric alpha actinin in cardiomyocytes 
were studied by immunohistochemistry. Unlike doxoru-
bicin single exposures, repeated exposures decreased the 
expression of both sarcomeric proteins and resulted in an 
Table 1  Overrepresented GO categories and pathways of k-means 
cluster genes
Term Gene count p value
Cluster 1
 GO:0000786—nucleosome 12 3.78E−09
 GO:0006334—nucleosome assembly 13 7.54E−09




 GO:0005783—endoplasmic reticulum 14 8.80E−05
 GO:0006984—ER-nuclear signalling 
pathway
4 2.76E−04
 GO:0005509—calcium ion binding 12 4.54E−04
Cluster 3
 GO:0030017—sarcomere 17 2.04E−09
 GO:0030016—myofibril 17 1.31E−08
 GO:0044449—contractile fibre part 17 1.70E−08




 hsa04115:p53 signalling pathway 16 9.09E−11
 GO:0043067—regulation of programmed 
cell death
45 1.80E−08
 GO:0042981—regulation of apoptosis 44 3.88E−08
Cluster 5
 GO:0019752—carboxylic acid metabolic 
process
18 1.04E−06
 GO:0006520—cellular amino acid meta-
bolic process
11 9.33E−06
 GO:0005583—fibrillar collagen 4 6.40E−05
Cluster 6
 GO:0000279—M phase 78 6.83E−66
 GO:0007067—mitosis 61 5.46E−55





irregular structure of the troponin and actinin filaments as 
compared to untreated cardiomyocytes (Fig. 5).
Discussion
For reliable evaluation of cardiotoxicity, human rel-
evant models are urgently required. Current preclinical 
cardiac safety studies have mainly relied on cardiac ion 
channels, especially the human ether-a-go–go (hERG) 
channel, as well as in vivo tests. In the present study, we 
have established an in vitro cardiotoxicity methodology 
for the monitoring of early as well as chronic cardio-
toxicity events at the cellular, functional and genomic 
level.
Doxorubicin is an established anti-cancer drug with 
well-known cardiac injury side effects. Its cumulative dose-
dependent cardiotoxicity (Appel et al. 2007; Menna et al. 
2012) leads to congestive heart failure (Haq et al. 1985; 
Ibrahim et al. 1999). Doxorubicin has a tendency to disturb 
cardiac rhythm and in some cases can cause life-threaten-
ing arrhythmia or even sudden death (Lacasse and Bolduc 
1992). The doxorubicin-induced disturbances in cardiac 
function can be detected within a few hours or within 
24–48 h following doxorubicin administration by electro-
cardiography in human and animal hearts (Dindogru et al. 
1978; Friess et al. 1985; Kehoe et al. 1978).
Our findings demonstrate that, unlike single exposure, 
repeated doxorubicin exposure caused arrhythmic beating 
on day 4 and induced substantial cytotoxicity accompanied 
with decreased beating amplitude on day 6. Doxorubicin-
induced arrhythmic beating indicates disturbed cardiac 
function, while the decreased amplitude reflects reduced 
contractile force. Our results are in agreement with find-
ings demonstrating that chronic doxorubicin administration 
reduces contractile function in rabbit hearts (Boucek et al. 
1997).
The GO and KEGG pathway analysis of our transcrip-
tomic studies showed that doxorubicin exposure preferen-
tially suppressed the expression of genes involved in car-
diac contraction and pathways related to cardiomyopathies. 
In addition, doxorubicin exposure also deregulated genes 
with enriched biological processes such as apoptosis, DNA 
damage and the oxidative stress response. These observa-
tions show that in addition to a general stress response, 
genes involved in sarcomeric and cardiac muscle contrac-
tion are more responsive to doxorubicin exposure. Car-
diomyocyte sarcomeres are highly organized structures of 
Table 2  Significantly enriched GO categories and pathways by commonly down-regulated genes between DOX-Day2 and DOX-Day6
Components Gene count p value Representative genes
GO term
 GO:0006936—muscle contraction 23 3.4E−11 SLC8A1, TCAP, ACTA1, MYL3, PGAM2, MYH7, MYH6, 
TNNI3, GJA5, EDNRA, DES, TNNT1, MYOM2, ARG2, RYR2, 
ASPH, KCNH2, SCN5A, KCNQ1, CASQ2, HRC, SGCA, MB
 GO:0005856—cytoskeleton 74 1.9E−10 KIF23, PRC1, TTK, AURKA, AURKB, GTSE1, KIF2C, FRMD5, 
DES, ANK2, LMOD2, MYC, TOP2A, LMOD3, TUBA1B, 
ASPM, KIF14, CDC6, CDK1, KIF11, ACTA1, KIF15, TPX2, 
LDB3, NUSAP1, MYH7, MYH6, MCM3, TNNT1
 GO:0030017—sarcomere 14 8.5E−07 MYL2, ACTA1, TCAP, MYL3, LDB3, FHL2, MYH7, MYH6, 
TNNI3, DES, TNNT1, ANK2, DMD, RYR2
 GO:0003013—circulatory system process 13 0.00262 MYL2, CORIN, TCAP, MYL3, MYH6, NPR3, ATP1A2, TNNI3, 
EDNRA, RYR2, KCNH2, SCN5A, KCNQ1
 GO:0016529—sarcoplasmic reticulum 5 0.01542 PYGM, SRL, RYR2, CASQ2, HRC
KEGG pathways
 hsa04260:Cardiac muscle contraction 11 1.98E−05 SLC8A1, MYL2, MYL3, ATP1B4, COX6A2, RYR2, MYH7, 
ATP1A2, MYH6, TNNI3, CACNA2D2
 hsa05410:Hypertrophic cardiomyopathy (HCM) 11 4.24E−05 SLC8A1, DES, MYL2, MYL3, DMD, RYR2, MYH7, MYH6, 
TNNI3, CACNA2D2, SGCA
 hsa05414:Dilated cardiomyopathy 11 8.42E−05 SLC8A1, DES, MYL2, MYL3, DMD, RYR2, MYH7, MYH6, 
TNNI3, CACNA2D2, SGCA
 hsa00240:Pyrimidine metabolism 8 0.009192 PRIM1, NME4, NME2, NME3, NME1-NME2, POLE2, RRM2, 
POLA1, TK1
 hsa05412:Arrhythmogenic right ventricular cardio-
myopathy (ARVC)
7 0.011314 SLC8A1, DES, DMD, RYR2, CACNA2D2, SGCA, CTNNA3
 hsa00230:Purine metabolism 10 0.013765 PRIM1, NME4, ADSSL1, NME2, NME3, NME1-NME2, 
POLE2, PDE1C, RRM2, POLA1, PAICS
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myofilaments and are involved in mechanical cardiac con-
traction. Our transcriptomic data showed significant down-
regulation of sarcomere genes in DOX-Day2 and DOX-
Day6 cells. Similar findings have also been reported in rat 
cardiomyocytes, in which chronic doxorubicin exposure 
induces significant degeneration of sarcomeres (Sussman 
et al. 1997). Our immunocytochemical analysis showed 
that compared to control and DOX-Day2 cells, repeated 
doxorubicin exposure resulted in decreased expression of 
cardiac troponin T and sarcomeric α-actinin proteins in 
DOX-Day6 cells, and this expression remained at lower 
levels even after doxorubicin washout in DOX-Day6WO. 
In addition, disorganization of myofibrillar structures in the 
DOX-Day6 cardiomyocytes has been observed. Doxoru-
bicin-induced myofibrillar disarray has also been reported 
in rat ventricular cardiomyocytes (Sussman et al. 1997; 
Sawyer et al. 2002).
Regulation of ion homeostasis is one of the essential 
functional elements during cardiac contraction. Intracel-
lular calcium (Ca2+) is the central regulator of cardiac 
Table 3  Significantly enriched GO categories and pathways by commonly up-regulated genes between DOX-Day2 and DOX-Day6
Components Gene count p value Representative genes
GO terms
 GO:0006333—chromatin assembly or  
disassembly
14 2.9E−07 HIST1H2AB, HIST2H2AA3, HIST2H2AA4, HIST4H4, HIST1H4L, 
HIST1H4 K, HIST1H2AG, HIST1H2AD, HIST1H2AE, HIST2H4A, 
HIST2H4B, H2BFS, HIST1H4A, HIST1H2BK, HIST1H4B, 
HIST1H2BI, HIST1H4E, HIST1H4F
 GO:0006974—response to DNA damage 
stimulus
19 8.6E−05 XRCC4, RAD51C, POLH, ZMAT3, RPS27L, RRM2B, SESN1, RNF8, 
TRIAP1, CDKN1A, CASP3, XPC, BTG2, BAX, UBR5, AEN, DDB2, 
PCNA, GADD45A
 GO:0033554—cellular response to stress 24 1.2E−04 GADD45A, XRCC4, RAD51C, POLH, ZMAT3, RPS27L, RRM2B, 
SESN1, RNF8, TRIAP1, DHRS2, GPX1, CASP3, CDKN1A, XPC, 
BTG2, AEN, UBR5, BAX
 GO:0008219—cell death 26 6.9E−04 ZMAT3, GADD45A, BAX, KIT, STK17A, TP53INP1, PMAIP1, APLP1, 
GPX1, TRIAP1, CASP3, TNFRSF11B, TMEM173, AEN, FAS, TRAF4, 
PHLDA1, RNF144B, GAS1, NTN1, TNFRSF10A, TNFRSF10C, 
TNFRSF10B, TNFRSF10D,
 GO:0006979—response to oxidative stress 9 0.00772 EGFR, GPX1, DHRS2, SDC1, RRM2B, NQO1, ETV5, ADA, OXR1
 GO:0050727—regulation of inflammatory 
response
6 0.01013 GPX1, A2 M, MASP1, ACE2, ITGA2, ADA
 GO:0005576—extracellular region 44 0.02673 GDF15, ACE2,FGFR2, ADAMTS17, A2 M, SORD, IGFBPL1, MASP1, 
NELL2, JAG1, KIT, LSR, ADA, APLP1, BDNF, TNFRSF11B, SER-
PINE2, COL27A1, FAS, NRG1, TFPI2, PCSK5, GFOD1, THBS4, 
EGFR, TMEFF2, FLRT2, ICAM4
 GO:0006916—anti-apoptosis 9 0.02699 TRIAP1, GPX1, BDNF, TNFRSF10D, BAX, FAS, NRG1, ANXA4, 
GSTP1
KEGG pathways
 hsa04115:p53 signalling pathway 16 5.2E−12 ZMAT3, RRM2B, PMAIP1, SESN2, SESN1, EI24, TP53I3, PPM1D, 
CDKN1A, CASP3, TNFRSF10B, BAX, DDB2, MDM2, FAS, 
GADD45A
 hsa04210:Apoptosis 9 4.6E−04 TNFRSF10A, CASP3, TNFRSF10C, TNFRSF10B, TNFRSF10D, BAX, 
ENDOD1, FAS, PRKX
Table 4  Long-term up-regulated genes enriched GO categories and pathways
Components Gene count p value Representative genes
GO term
 GO:0006917—induction of apoptosis 5 0.0030 TNFRSF10A, CDKN1A, ZMAT3, RRM2B, FAS
 GO:0033554—cellular response to stress 6 0.0039 XRCC4, CDKN1A, ZMAT3, RRM2B, NEFL, ETV5
 GO:0006974—response to DNA damage stimulus 4 0.0338 XRCC4, CDKN1A, ZMAT3, RRM2B
KEGG pathways
 hsa04115:p53 signalling pathway 5 4.7E−05 CDKN1A, ZMAT3, MDM2, RRM2B, FAS
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contraction, and its homeostasis is tightly regulated by 
Ca2+ ion channels, Ca+2 receptors and Ca+2 binding pro-
teins. Our data showed down-regulation of Ca2+-transport-
ing genes such as RYR2, SLC8A1, CACNA1G, CACNA2D2 
and ITPR1 in doxorubicin-exposed hiPSC-CMs. Differen-
tial regulation of two calcium release channels (RYR2 and 
ITPR1) has been reported during end stage heart failure (Go 
et al. 1995). Chronic rabbit heart studies have shown altera-
tions in Ca2+ release causing abnormalities of contractions 
and relaxation in doxorubicin-induced cardiomyopathy 
(Dodd et al. 1993). In addition, we found down-regulation 
of sodium (Na+) and potassium (K+) ion channel encoding 
genes, such as KCNQ1, KCNK3, KCNN2, KCNH2, SCN2B 
and SCN5A. Deregulated Na+ and K+ ion channels play 
an important role in cardiac arrhythmias and heart failure 
(Remme and Bezzina 2010; Nabauer and Kaab 1998). In 
summary, our results are in accordance with animal and 
clinical studies demonstrating that doxorubicin induces dis-
turbances in cardiac calcium homeostasis as well as altered 
sodium and potassium ion channel activity. In the present 
study, doxorubicin exposure significantly deregulated ion 
homeostasis maintaining genes at the mRNA level accom-
panied with functional changes in the beating behaviour of 
hiPSC-CMs.
Mitochondrial dysfunction has been suggested to be 
involved in doxorubicin-induced cardiotoxicity. How-
ever, the exact mechanisms of the suppressive effects by 
doxorubicin on the mitochondrial electron transport chain, 
oxidative metabolism and ATP synthesis are not fully 
understood. As a crucial component of the mitochondrial 
electron transport chain, cytochrome C oxidase (CCo) and 
uncoupling protein (UCP) activity influences mitochon-
drial function at the ATP level. In rat hearts, doxorubicin 
treatment reduced CCo subunit expression (Chandran et al. 
2009) and also down-regulated Ucp2 and Ucp3 expression 
(Bugger et al. 2011). Down-regulation of UCPs and CCo 
genes showed an inverse relationship with increased oxi-
dative stress (Akhmedov et al. 2015; Bugger et al. 2011; 
Srinivasan and Avadhani 2012); CCo dysfunction also has 
a direct effect on cellular ATP levels. In agreement with 
these observations, our data also indicated a down-regu-
lation of UCP2 and CCo (Cytochrome C Oxidase Subu-
nit VIa Polypeptide 2) expression, whereas up-regulation 
was observed for oxidative stress-responsive genes such 
as NQO1, OXR, GCH1 and GPX1 in doxorubicin-exposed 
hiPSC-CMs (supplementary Fig. S5). Similarly to our 
findings, the reduced activity of creatine kinase muscle 
(CKM) and myoglobin (MB) has been reported in human 
failing hearts (Braunlin et al. 1986; Nascimben et al. 1996; 
Obrien et al. 1992). Decreased levels of CKM impair the 
ATP delivery process to energy-consuming systems, and 
decreased levels of MB disturb oxygen diffusion and the 
mechanical functions of the cardiac muscle. In conclu-
sion, the present results suggest that doxorubicin induces 
increased oxidative stress and impairs mitochondrial ATP 
synthesis and delivery in cardiomyocytes. Overall, these 
intracellular mechanisms contribute to the impaired car-
diac function observed after doxorubicin treatment in can-
cer patients.
In accordance with our findings, the expression level 
of apoptosis genes including BAX and FAS has also been 
found to be up-regulated in human failing hearts (Latif 
et al. 2000; Sheppard et al. 2005). Increased expression of 
BAX and FAS may induce apoptosis and reduce the chances 
of myocardial recovery. Similarly to our results, increased 
expression levels of ACE2, NRG1, DUSP4 and LIF have 
also been found in human heart failure (Goulter et al. 2004; 
Yan and Morgan 2011; Communal et al. 2002; Eiken et al. 
2001). KCNJ2 is also up-regulated in human dilated car-
diomyopathy (Szuts et al. 2013). Notably, GDF15 and 
GPNMB (patent publication number—WO2012072752 
A1) have been proposed as diagnostic biomarkers of heart 
failure (Wang et al. 2010; Kempf and Wollert 2009; Khan 
et al. 2009) and were also up-regulated in our model sys-
tem. Therefore, the gene expression responses observed 
in our established in vitro system showed a high degree of 
similarity to those of the human heart in vivo.
Fig. 4  Venn diagrams representing number of common and drug-
specific deregulated genes following 48 h exposure to anthracyclines 
in hiPSC-CMs. a Commonly down-regulated 27 genes and b com-
monly up-regulated 8 genes among doxorubicin (DOX), daunorubicin 
(DAUNO) and mitoxantrone (MITO) groups
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The Venn diagram analysis of differentially expressed 
genes in cells exposed to doxorubicin, daunorubicin and 
mitoxantrone exhibited an overlap of 27 down- and 8 up-
regulated genes. The 27 down-regulated genes are mainly 
involved in sarcomere structure and the regulation of 
ion homeostasis. Up-regulated genes mainly indicate a 
general stress response, and they included stress mark-
ers such as BAX, FAS, GPX1 and ZMAT3. This observa-
tion may help to better understand cellular mechanisms 
underlying late apoptosis inducing cardiac cell loss many 
years after anthracycline treatment. Although GDF15 has 
been reported to represent a biomarker for heart failure, 
elevated levels have also been found in the cell systems 
of liver, lung and kidney injury (Hsiao et al. 2000; Zim-
mers et al. 2005). Thus, it can be interpreted as a marker 
which indicates cell injury in multiple tissues. The iden-
tified 35 genes in the overlap of all three anthracyclines 
represent an anthracycline-responsive gene consensus 
expression signature and could be applied as a predictive 
toxicity signature for potential cardiotoxicants that act 
Table 5  Gene expression 
studies (fold regulation) by real-
time PCR in hiPSC-CMs after 
48 h exposure of doxorubicin 
(156 nM), daunorubicin 
(10 nM) and mitoxantrone 
(3 nM)
The numerical data represent the fold regulation values compared to controls. The p value is calculated 
based on a Student’s t test of the Ct values (n = 3). p value ≤0.05 is considered significant
Gene symbol Fold regulation p value
Doxorubicin Daunorubicin Mitoxantrone Doxorubicin Daunorubicin Mitoxantrone
ACTA1 −211.2 −5.0 −11.7 7.5E−05 9.7E−03 4.6E−03
TNNT1 −31.1 −2.7 −2.7 3.4E−05 6.8E−03 7.3E−03
HRC −467.6 −38.1 −48.1 8.2E−04 5.2E−04 2.9E−03
MYOM2 −50.0 −9.7 −22.1 6.2E−04 2.1E−03 9.8E−03
MYH6 −290.8 −60.3 −76.8 1.5E−04 3.2E−04 5.5E−04
MYH7 −2684.9 −182.1 −179.4 2.7E−05 6.9E−05 3.9E−04
ANK2 −87.1 −10.4 −3.5 2.2E−03 5.4E−03 9.1E−02
LDB3 −128.4 −12.0 −19.3 9.4E−05 2.4E−04 5.3E−04
DMD −9.6 −10.4 −22.4 2.1E−03 4.8E−04 7.5E−04
NRAP −21.8 −19.4 −22.8 9.5E−05 2.3E−04 1.5E−03
ATP1A2 −248.2 −9.3 −25.6 1.9E−02 2.3E−03 8.3E−03
KCNQ1 −29.1 −4.2 −4.9 1.3E−04 3.1E−03 8.2E−03
KCNH2 −29.1 −5.9 −6.3 2.6E−04 8.9E−03 1.3E−02
SCN2B −19.7 −4.7 −5.1 7.6E−04 8.5E−03 1.1E−02
SCN5A −119.9 −37.6 −28.2 3.1E−04 1.9E−03 1.8E−03
CACNA2D2 −52.4 −68.3 −59.4 8.1E−03 5.0E−03 4.2E−03
PYGM −457.1 −8.2 −11.8 1.4E−04 4.4E−04 4.8E−04
CKM −71.1 −2.5 −1.9 6.1E−05 2.9E−03 3.1E−02
MURC −22.8 −9.6 −7.4 1.3E−03 8.3E−04 1.0E−03
ERBB3 −20.5 −7.3 −5.0 2.6E−04 2.9E−03 2.7E−03
JAK2 −18.6 −3.2 −4.4 4.9E−04 1.8E−02 1.8E−03
PPP1R3A −15.2 −3.5 −7.9 5.0E−03 1.9E−03 1.0E−02
RYR2 −136.7 −26.9 −82.5 1.6E−03 1.3E−04 5.3E−03
IRX4 −21.4 −5.6 −6.2 2.4E−04 7.5E−03 3.4E−03
CORIN −68.8 −5.9 −15.9 5.9E−04 3.6E−03 2.9E−03
CACNA1G −75.5 −62.0 −42.4 6.5E−04 2.1E−03 1.7E−04
PRDM16 −35.3 −28.5 −35.8 1.3E−02 6.2E−04 9.8E−04
BAX 7.72 3.91 2.93 2.9E−04 3.7E−04 5.5E−04
ZMAT3 3.3 3.4 2.0 5.3E−03 3.4E−03 1.6E−02
GDF15 8.8 2.6 6.9 5.2E−04 1.5E−02 8.7E−03
FAS 18.3 7.3 5.7 3.1E−05 3.6E−05 4.2E−05
PRKX 1.9 2.6 2.1 7.3E−02 1.5E−02 1.1E−02
DUSP4 15.8 3.1 2.5 1.9E−03 8.7E−03 2.2E−02
KCNJ2 18.7 2.3 2.8 1.3E−04 1.8E−02 6.4E−03
GPX1 15.8 2.4 2.6 1.6E−04 7.3E−03 2.6E−03
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by similar mechanisms as doxorubicin, daunorubicin or 
mitoxantrone.
In the present study, a concentration of 156 nM doxo-
rubicin was chosen because in the hiPSC-CMs this con-
centration compromises the contractility without causing 
major cytotoxic effects. At doses of bolus administration of 
doxorubicin varying between 15 and 90 mg/m2, the initial 
maximal plasma concentrations in patients are approxi-
mately 5 µM (Gewirtz 1999). After this initial peak, the 
plasma concentration of doxorubicin decreases rapidly, to 
the range of 25–250 nM, within 1 h. Similar plasma con-
centrations have also been reported in patients receiving 
continuous infusions of doxorubicin (Gewirtz 1999). In 
addition, after a 50 mg/m2 intravenous injection in adult 
acute myeloid leukaemia patients, a daunorubicin peak 
plasma concentration range from 120 to 560 nM on day 
1 and 8 to 610 nM on day 3 has been observed (Lofgren 
et al. 2007). The mitoxantrone peak plasma concentrations 
have been reported to vary from 0.46 to 2.49 µM after 1 h 
infusion of mitoxantrone (12 mg/m2) and then decrease 
Fig. 5  Immunohistochemistry of cardiac troponin T and sarcomeric 
cardiac α-actinin proteins in control, doxorubicin-exposed and wash-
out hiPSC-CMs. Red and green colours indicate cardiac troponin T 
and sarcomeric alpha actinin staining, respectively. Blue colour indi-
cates nuclear staining. Immunofluorescence results demonstrate a 
significant decrease in both protein expression levels in DOX-Day6 




rapidly to around 10 nM within 5 h (Sundman-Engberg 
et al. 1993). Therefore, the concentration chosen in the pre-
sent study is within the therapeutic range of anthracyclines 
therapy.
In summary, the results obtained by anthracyclines in 
hiPSC-CMs recapitulated the disturbed cardiac function 
observed in vivo and in clinical studies. Doxorubicin-
induced adverse effects on cardiac function can be detected 
much earlier at the genomic level before cytotoxicity and 
arrhythmia can be observed. The combined application of 
hiPSC-CMs, the xCELLigence RTCA Cardio system and 
transcriptomics resulted in the identification of an anthra-
cycline consensus signature representing early biologi-
cal processes that significantly contribute to better under-
standing of the cardiotoxic effects of compounds both at 
a cellular and molecular level. The present methodology 
can allow for first-line in vitro preclinical tests and reduce 
animal usage in drug safety studies and the costs of safety 
evaluation. Although it is very likely that the methodol-
ogy possesses a low false negative rate for severely car-
diotoxic compounds, however, whether this approach can 
avoid false negatives for mildly cardiotoxic compounds 
and false positives for non-cardiotoxic compounds should 
be demonstrated by screening of several non- and mild 
cardiotoxicants.
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